Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$1.60 -7.5%	$1.62	$1.17 ▼ $25.12	$10.48M	-0.12	1.21 million shs	138,929 shs
CODX Co-Diagnostics	$0.26 -6.4%	$0.31	$0.23 ▼ $2.23	$9.39M	0.57	242,996 shs	859,499 shs
INO Inovio Pharmaceuticals	$1.96 +0.5%	$1.96	$1.42 ▼ $12.33	$71.51M	1.34	628,304 shs	773,501 shs
NVAX Novavax	$6.41 +1.7%	$6.74	$5.01 ▼ $17.81	$1.02B	2.8	6.46 million shs	4.82 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	-7.51%	+2.56%	+15.11%	-31.33%	-91.80%
CODX Co-Diagnostics	-6.40%	-5.11%	+2.63%	-43.23%	-82.90%
INO Inovio Pharmaceuticals	+0.51%	-2.00%	-1.01%	+2.08%	-77.10%
NVAX Novavax	+1.75%	-7.64%	-9.85%	-15.66%	-53.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTAI BioXcel Therapeutics	3.5187 of 5 stars	3.3	2.0	4.5	0.0	1.7	0.6
CODX Co-Diagnostics	3.8171 of 5 stars	3.5	3.0	4.4	0.6	0.0	1.3
INO Inovio Pharmaceuticals	3.5448 of 5 stars	3.3	2.0	4.3	2.2	0.0	0.6
NVAX Novavax	4.4042 of 5 stars	3.1	2.0	4.7	1.3	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$42.60	2,562.50% Upside
CODX Co-Diagnostics	3.00	Buy	$5.50	2,001.64% Upside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	397.45% Upside
NVAX Novavax	2.29	Hold	$17.00	165.21% Upside

Current Analyst Ratings Breakdown

Latest BTAI, INO, CODX, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
4/28/2025	CODX Co-Diagnostics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	CODX Co-Diagnostics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/28/2025	CODX Co-Diagnostics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$2.27M	4.27	N/A	N/A	($30.01) per share	-0.05
CODX Co-Diagnostics	$3.91M	2.25	N/A	N/A	$1.70 per share	0.15
INO Inovio Pharmaceuticals	$220K	326.70	N/A	N/A	$1.90 per share	1.03
NVAX Novavax	$1.21B	0.85	N/A	N/A	($3.89) per share	-1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$59.60M	-$13.55	N/A	N/A	N/A	-2,163.18%	N/A	-83.80%	8/5/2025 (Estimated)
CODX Co-Diagnostics	-$37.64M	-$1.17	N/A	N/A	N/A	-1,025.45%	-60.16%	-52.69%	8/6/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.42	80.13	0.07	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)

Latest BTAI, INO, CODX, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/12/2025	Q1 2025	BTAI BioXcel Therapeutics	-$2.72	-$1.50	+$1.22	-$1.50	$0.35 million	$0.17 million
5/8/2025	Q1 2025	CODX Co-Diagnostics	-$0.33	-$0.24	+$0.09	-$0.24	$0.38 million	$0.05 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
3/27/2025	Q4 2024	BTAI BioXcel Therapeutics	-$4.36	-$3.57	+$0.79	-$3.57	$0.72 million	$0.30 million
3/27/2025	Q4 2024	CODX Co-Diagnostics	-$0.34	-$0.36	-$0.02	-$0.36	$0.38 million	$0.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
CODX Co-Diagnostics	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	1.48	1.45
CODX Co-Diagnostics	N/A	4.43	4.23
INO Inovio Pharmaceuticals	N/A	2.63	2.63
NVAX Novavax	N/A	2.06	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
CODX Co-Diagnostics	14.99%
INO Inovio Pharmaceuticals	26.79%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	21.20%
CODX Co-Diagnostics	8.40%
INO Inovio Pharmaceuticals	2.30%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
CODX Co-Diagnostics	100	33.57 million	30.75 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable

BTAI, INO, CODX, and NVAX Headlines

Recent News About These Companies

Novavax Faces Challenges Amid Stock Decline

June 21 at 10:23 AM | tipranks.com

Novavax (NVAX) Ascends While Market Falls: Some Facts to Note

June 20 at 6:46 PM | zacks.com

Brokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $19.20

June 20 at 1:37 AM | americanbankingnews.com

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

June 19 at 10:01 AM | zacks.com

Novavax slips as Citi launches with Sell rating on pipeline concerns

June 17, 2025 | seekingalpha.com

Novavax slips as Citi launches with Sell rating on pipeline concerns

June 17, 2025 | msn.com

Novavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?

June 17, 2025 | marketbeat.com

Novavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at Citigroup

June 17, 2025 | marketbeat.com

Novavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Moderate Buy" by Brokerages

June 17, 2025 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)

June 14, 2025 | theglobeandmail.com

Novavax: New Vaccine, Same Old Story - Still A Sell

June 13, 2025 | seekingalpha.com

Novavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLC

June 13, 2025 | marketbeat.com

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

June 12, 2025 | zacks.com

Novavax's COVID-flu combo vaccine shows strong immune response in trial

June 12, 2025 | msn.com

Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals

June 12, 2025 | thepharmaletter.com

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 11, 2025 | seekingalpha.com

Novavax’s COVID-flu combo vaccine shows strong immune response

June 11, 2025 | msn.com

Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall

June 11, 2025 | investing.com

Novavax posts immune data to back COVID-flu combo shot and standalone flu shot

June 11, 2025 | msn.com

Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates

June 11, 2025 | finance.yahoo.com

Novavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’

June 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, INO, CODX, and NVAX Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

$1.60 -0.13 (-7.51%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.63 +0.03 (+1.87%)

As of 06/20/2025 07:29 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Co-Diagnostics NASDAQ:CODX

$0.26 -0.02 (-6.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.28 +0.02 (+7.37%)

As of 06/20/2025 08:00 PM Eastern

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Inovio Pharmaceuticals NASDAQ:INO

$1.96 +0.01 (+0.51%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.26%)

As of 06/20/2025 07:49 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Novavax NASDAQ:NVAX

$6.41 +0.11 (+1.75%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.40 0.00 (-0.08%)

As of 06/20/2025 07:50 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time